Oculogenex

La Habra, United States Founded: 2020 • Age: 6 yrs
Gene therapy for ophthalmological disorders, including macular degeneration, is developed.

About Oculogenex

Oculogenex is a company based in La Habra (United States) founded in 2020 by Ram Ramkumar.. Oculogenex offers products and services including Gene Therapy for Macular Degeneration. Oculogenex operates in a competitive market with competitors including EyePoint Pharmaceuticals, Rezolute, Molecular Partners, Aviceda Therapeutics and IVERIC bio, among others.

  • Headquarter La Habra, United States
  • Founders Ram Ramkumar
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
    $256 K (USD), Grant

    May 01, 2021

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Oculogenex

Oculogenex offers a comprehensive portfolio of products and services, including Gene Therapy for Macular Degeneration. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Investigational therapy to stop vision degeneration in retinal diseases.

People of Oculogenex
Headcount 1-10
Employee Profiles 3
Employee Profiles
People
Hema Ramkumar
Founder & CEO
People
Ram Ramkumar
Co-Founder, Business Development & COO
People
Zhongyang Lu
Lab Director

Unlock access to complete

Teams

Unlock access to complete

Funding Insights of Oculogenex

  • Total Funding
  • Total Rounds 1
  • Last Round Grant — $256,000
  • First Round

    (01 May 2021)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
May, 2021 Amount Grant - Oculogenex Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Oculogenex

Oculogenex has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include National Science Foundation. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
A government-backed foundation providing seed-stage investments to support small businesses.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Oculogenex

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Oculogenex

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Oculogenex Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Oculogenex

Oculogenex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as EyePoint Pharmaceuticals, Rezolute, Molecular Partners, Aviceda Therapeutics and IVERIC bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Small molecule therapeutics for ophthalmic disorders are developed.
domain founded_year HQ Location
Therapies for metabolic and orphan diseases are developed by Rezolute.
domain founded_year HQ Location
Therapeutic solutions for diseases are developed using DARPin technology.
domain founded_year HQ Location
Biotherapeutics for glycol-immune diseases are developed across multiple therapeutic areas.
domain founded_year HQ Location
Gene therapy solutions for retinal diseases are developed.
domain founded_year HQ Location
Therapies for ophthalmological diseases are developed to restore vision.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Oculogenex

Frequently Asked Questions about Oculogenex

When was Oculogenex founded?

Oculogenex was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Oculogenex located?

Oculogenex is headquartered in La Habra, United States. It is registered at La Habra, California, United States.

What does Oculogenex do?

Oculogenex was founded in 2020 and is based in La Habra, United States. Operations focus on the biotechnology sector, where gene therapies for eye disorders are developed. An ocular regenerative product is delivered via intravitreal injection to address central vision degeneration in macular degeneration patients. Development targets ophthalmological conditions through targeted genetic interventions.

Who are the top competitors of Oculogenex?

Oculogenex's top competitors include EyePoint Pharmaceuticals, Rezolute and Molecular Partners.

What products or services does Oculogenex offer?

Oculogenex offers Gene Therapy for Macular Degeneration.

Who are Oculogenex's investors?

Oculogenex has 1 investor. Key investors include National Science Foundation.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available